Phase 2
Completed N=52
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
Source: ClinicalTrials.gov NCT01458249 ↗Enrolled (actual)
52
Serious AEs
29.4%
Results posted
Mar 2016
Primary outcomePrimary: Progression-free Rate at 12 Weeks (PFR12wks) — 60.0; 31.3 Percentage of participants
Summary
The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a combination therapy).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Rate at 12 Weeks (PFR12wks) |
60.0; 31.3 | — |
| SECONDARY Progression-Free Survival (PFS) |
5.52; 2.01 | — |
| SECONDARY Overall Survival (OS) |
16.95; 7.64 | — |
| SECONDARY Objective Response Rate (ORR) |
0; 0 | — |
| SECONDARY Disease Control Rate (DCR) |
80.0; 50.0 | — |
| SECONDARY Clinical Benefit Rate (CBR) |
74.3; 50.0 | — |
| SECONDARY Durable Stable Disease (SD) Rate (dSDR) |
74.3; 50.0 | — |
| SECONDARY Best Overall Response (BOR) |
0; 0; 0; 0; 80.0; 50.0 | — |
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically confirmed soft tissue sarcoma of high or intermediate grade
- Documented evidence of advanced or metastatic soft tissue sarcoma, not amenable to surgery or radiotherapy
- Within 6 months from the radiographic evidence of disease progression by RECIST criteria in the last chemotherapy regimen for advanced or metastatic soft tissue sarcoma
- Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Subjects who received at least one standard chemotherapy for advanced soft tissue sarcoma (an anthracycline or an ifosfamide monotherapy, or a combination therapy)
- Subjects aged ≥ 20 years at the time of informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Adequate organ function
- Voluntary agreement to provide written informed consent
Exclusion Criteria
- A history of malignancies or recurrence within 5 years after the remission
- Significant cardiovascular impairment
- Any serious concomitant illness or infection requiring treatment.
- Hypersensitivity to either halichondrin B or halichondrin B chemical derivatives or both.
- Subjects who have previously participated in a study with eribulin (whether treated with eribulin or not).
- Any medical or other condition which, in the opinion of the principal investigator, will preclude participation in a clinical trial.
- Subjects who have received any anti-cancer therapy, including surgery, radiotherapy, immunotherapy, cytotoxic, hormonal, biological (including humanized antibodies) and targeted agents within 21 days, or any investigational agent within 30 days, prior to the first dose of study drug.
- Subjects who have not recovered from toxicities as a result of prior anti-cancer therapy to ≤ Grade 1, according to Common Terminology Criteria for Adverse Events (CTCAE), except for peripheral neuropathy of Grade 2 and alopecia.
- Subjects with known cerebral metastases with clinical symptoms or requiring treatment.
- Pre-existing peripheral neuropathy > CTCAE Grade 2.
- Female subjects must not be pregnant with a negative by the pregnancy test at Screening, or breastfeeding.
- Subjects participating in other clinical trials
Data sourced from ClinicalTrials.gov (NCT01458249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.